Targeted Approach to Langerhans Cell Histiocytosis (LCH) Using MEK Inhibitor, Trametinib

Launched by COOK CHILDREN'S HEALTH CARE SYSTEM · Aug 30, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at a new treatment for Langerhans Cell Histiocytosis (LCH), a rare condition that affects certain immune cells in the body. The researchers want to find out if trametinib, a targeted therapy, is safe and effective for children who have recently been diagnosed with LCH or for those whose condition has come back or didn’t respond to previous treatments. The trial is currently recruiting participants who are between the ages of 1 and 29 years and have had their diagnosis confirmed through a biopsy.

To be eligible to join the study, patients must have specific health conditions, such as good heart function and overall health, as determined by a doctor. Participants will receive trametinib and be monitored throughout the study to see how well they respond to the treatment. It's important to note that women who can become pregnant and men must use birth control during the study and for four months after treatment ends. This trial aims to provide a better understanding of how trametinib can help children with LCH and improve their quality of life.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• * Diagnosis/disease status:
• • Patients with newly diagnosed Langerhans cell histiocytosis (LCH) OR
• • Patients with relapsed or refractory disease OR
• • Patients with newly diagnosed or relapsed/refractory disease who are receiving the liquid formula of trametinib OR
• • Patients who have been receiving trametinib as a treatment for LCH since January 1, 2020 may be included in the observational chart review to track long-term follow-up. Eligibility for chart review cohort will include receiving trametinib as treatment.
• • Diagnosis confirmed with biopsy prior to start of treatment
• • Patient must have adequate cardiac function evident through Echocardiogram (ECHO) and Electrocardiogram (EKG) within 30 days of starting treatment.
• • Shortening fraction of ≥ 27% by echocardiogram or
• • Ejection fraction of ≥ 50% by gated radionuclide study
• • QTC \< 480 msec
• • Performance status: Patients must have a performance status corresponding to ECOG scores of 0, 1, or 2. Use Karnofsky ≥ 50% for patients \> 16 years of age and Lansky ≥50% for patients ≤16 years of age.
• * Adequate organ and marrow function as defined below:
• • Absolute Neutrophil count ≥ 1,500/μL
• • Platelets ≥ 100x103/μL
• • Total bilirubin ≤ 1.5X ULN for age
• • AST/ALT ≤ 2.5 X ULN for age
• • Serum creatinine based on age/gender
• • Hemoglobin ≥ 8 g/dL
• • Patients with bone marrow disease must have hemoglobin ≥ 8 g/dL with transfusion support allowed
• • Women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 4 months after the last dose. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.
• • Ability to understand study procedures and to comply with them for the entire length of the study.
• Exclusion Criteria:
• * Patients diagnosed with Low-Risk True Skin Only or a Single Bone lesion that does not require treatment and will only be observed will not be eligible, with the exception of CNS-risk lesions/special site disease or functionally critical lesions:
• • CNS-risk/special site includes: Sphenoid, Mastoid, Orbital, zygomatic, ethmoid, maxillary, or temporal bones, the cranial fossa, pituitary gland or neurodegenerative disease, odontoid peg, vertebral lesion with intraspinal soft tissue extension
• • Functionally critical: A single lesion not described above which may cause "functionally critical anatomic abnormality" wherein attempts at local therapy would cause unacceptable morbidity. This can be at the discretion of the Principal Investigator.
• * Patients whose genetic testing reveals a class 3 MAP2K1 mutation:
• • I103_K104del
• • E102_I103del
• • L98_K104delinsQ
• • L98_I103del
• • I99_K104del
• • Patients who present with jaundice at diagnosis.
• • Patients who are pregnant or breastfeeding are not eligible. Women of childbearing potential must receive a negative pregnancy test within 14 days of starting treatment or the patient will not be eligible.
• • Patients who are allergic to trametinib
• • Current drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements.
• • Inability or unwillingness of patient or parent/legally authorized representative to give written informed consent.